We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bioimpedance Spectroscopy Preferred for Post-Breast Surgery Lymphedema Risk

By LabMedica International staff writers
Posted on 04 Jun 2019
Interim results from a study that compared bioimpedance spectroscopy (BIS) to the classical tape measure for assessing a woman’s risk for developing lymphedema after breast cancer surgery strongly suggested that BIS was the preferred method.

BIS is a painless and relatively simple measurement method. More...
The measured data can be used to determine the amount of fluids in the body as well as estimate body composition. The measurement is based on an assumption that an electric current at low frequencies cannot permeate cells and travels through extra-cellular space only and is used to measure extracellular water (ECW). An electric current at high frequencies permeates cell membranes and is used to measure total body water (TBW).

Breast cancer-related lymphedema (BCRL) represents a major source of morbidity among breast cancer survivors. Lymphedema causes swelling in the arm, can be physically debilitating, and puts women at greater risk for infections as well as psychological stress.

Investigators at Vanderbilt University (Nashville, TN, USA) moderated an international randomized controlled trial comparing lymphedema progression rates using volume measurements calculated from the circumference using a tape measure (TM) or by BIS. The trial included 508 participants who had been monitored for a year or longer. Participants identified at risk for lymphedema received compression sleeves and gauntlets and were instructed to wear them 12 hours daily for 28 days to prevent progression to lymphedema. Patients who developed lymphedema reached their endpoint with the trial and were referred to clinicians for complex decongestive physiotherapy (CDP).

Interim results obtained during the trial demonstrated that post-treatment surveillance with BIS reduced the absolute rates of progression of BCRL requiring CDP by approximately 10%, a clinically meaningful improvement. These results supported the concept of post-treatment surveillance with BIS to detect subclinical BCRL and initiate early intervention.

“The bioimpedance device measures lymphatic fluid, and the tape measures everything,” said senior author Dr. Sheila Ridner, professor of nursing science at Vanderbilt University. “It takes more lymphatic fluid to make your whole arm volume change than it does to make the device pick up changes. The device is just more sensitive to changes in lymphatic fluid.”

“We had statistically significant more people trigger an intervention that were in the tape group than in the BIS group, which was contrary to what many people thought would have happened in the study. One of the concerns about BIS in general was that it might generate false positives and we might psychologically distress people,” said Dr. Ridner. “That was never my experience in the 15 to 16 years I have been working with the technology.”

The interim report was published in the May 3, 2019, online edition of the journal Annals of Surgical Oncology.

Related Links:
Vanderbilt University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.